You are now leaving Abacavir HSR Support. ViiV Healthcare does not recommend, endorse or accept liability for sites controlled by third parties.
Clinical diagnosis of suspected hypersensitivity to abacavir remains the basis for clinical decision making
- HLA-B*5701 screening for risk of abacavir hypersensitivity should never be substituted for appropriate clinical vigilance and patient management in individuals receiving abacavir
- HLA-B*5701 testing must not be used as a diagnostic test after a patient has started treatment with abacavir